Xiao-qun Zhu

Dr. Xiao-qun Zhu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2024 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
XZXia Zhou
Xia Zhou
WYWen‐Wen Yin
Wen‐Wen Yin
CHChao‐Juan Huang
Chao‐Juan Huang
SSSi‐Lu Sun
Si‐Lu Sun
ZLZhi‐Wei Li
Zhi‐Wei Li
ZSZhongwu Sun
Zhongwu Sun
Background: Both Alzheimer's disease (AD) and cerebral small vessel disease (CSVD) manifest in cognitive impairment and gait disorders. The precise similarities and differences in gait characteristics and underlying neuroimaging mechanisms remain unclear.Methods: A total of 399 participants were enrolled: 132 with probable AD, including 98 with mild cognitive impairment due to AD (AD‐MCI) and 34 with AD dementia, and 185 with CSVD and 82 healthy controls. CSVD patients with cognitive impairment, including subcortical vascular mild cognitive impairment (svMCI) and subcortical vascular dementia, were grouped as subcortical vascular cognitive impairment (SVCI). Voxel‐based morphology analysis assessed grey matter volume (GMV), while cerebral blood flow (CBF) was derived from 3D‐arterial spin labelling data. Gait metrics included the timed up and go (TUG) test, dual‐task TUG (DTUG) test, Berg balance scale (BBS), dual‐task cost (DTC), step length, gait speed, cadence and coefficient of variation of gait. The relationships among structural and perfusion variations, gait metrics and cognitive function were examined.Results: SVCI patients exhibited greater gait impairments and variability than those with AD, while AD patients experienced higher DTC (p < 0.05). These differences were most evident in the MCI stage. In AD, gait speed correlated with GMV in the left middle occipital gyrus (F = 6.149), middle temporal gyrus (F = 4.595), right precuneus (F = 5.174) and other regions (all p < 0.025). In SVCI, gait speed was linked to thalamic GMV (F = 6.004, p < 0.025). Altered CBF in the parietal lobe and precuneus was associated with DTUG (F = 5.672), gait speed (F = 4.347) and BBS (F = 4.153) in AD, while cerebellar CBF related to TUG (F = 6.042), DTUG (F = 4.857) and BBS (F = 7.097) in SVCI (all p < 0.025). In AD‐MCI, memory mediated the effect of hippocampal volume on DTC (indirect effect: −2.432, 95% CI [−5.503, −0.438]), while executive function (indirect effect: −2.920, 95% CI [−7.227, −0.695]) and processing speed (indirect effect: −2.286, 95% CI [−5.174, −0.484]) mediated the effect on DTUG. In svMCI, executive function mediated the effect of thalamic volume on step length (indirect effect: 2.309, 95% CI [0.486, 4.685]) and gait speed (indirect effect: 2.029, 95% CI [0.142, 4.588]), while processing speed mediated the effect on step length (indirect effect: 1.777, 95% CI [0.311, 4.021]).Conclusions: Different gait disorder characteristics and mechanisms were observed in AD and CSVD patients. In AD, gait is associated with volume/perfusion in posterior brain regions, whereas in SVCI, it relates to thalamic volume and cerebellar perfusion. Cognitive impairment mediates the effect of hippocampal and thalamic volumes on gait in AD‐MCI and svMCI, respectively.

13 November 2025 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
LALulu Ai
Lulu Ai
ZLZhiwei Li
Zhiwei Li
HHHuipeng Huang
Huipeng Huang
CHChaojuan Huang
Chaojuan Huang
SCShujian Chen
Shujian Chen
ZSZhongwu Sun
Zhongwu Sun
Objective: While emerging evidence links glymphatic dysfunction to cerebral small vessel disease (CSVD), its clinical relevance remains poorly defined. This study aimed to investigate the relationships among glymphatic function, perivascular space (PVS), and cognitive performance in CSVD. Methods: We enrolled 120 CSVD patients [52 with no cognitive impairment (CSVD-NCI) and 68 with mild cognitive impairment (CSVD-MCI)] and 40 healthy controls (HCs). Glymphatic function was assessed using the left ALPS index derived from diffusion tensor imaging analysis along the perivascular space (DTI-ALPS). Group comparisons in the ALPS index and PVS volume fraction (VF), and correlations among glymphatic function, PVS burden, and cognition were analyzed. Results: Compared to HCs, CSVD patients showed decreased ALPS index and increased PVS VF in basal ganglia (BG), caudate, putamen, and hippocampus, with more pronounced alterations in the left hemisphere. The ALPS index was inversely correlated with PVS VF in the BG ( r = −0.232, p = 0.014), thalamus ( r = −0.213, p = 0.024), caudate ( r = −0.221, p = 0.019), and putamen ( r = −0.210, p = 0.026) in CSVD. Furthermore, a lower ALPS index was associated with poorer performance in global cognition ( r = 0.312, p = 0.001), executive function ( r = 0.242, p = 0.012), processing speed ( r = 0.264, p = 0.006), and visuospatial function ( r = 0.272, p = 0.004). Finally, the ALPS index partially mediated the association between putamen-PVS VF and global cognitive function, especially in the left hemisphere. Conclusion: Our findings demonstrate that impaired glymphatic function was associated with enlarged BG-PVS, especially in the putamen, and worse cognitive performance, highlighting its potential role in disease progression and cognitive decline in CSVD.

6 August 2025 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
YWYa-Yu Wang
Ya-Yu Wang
MZMan Zhang
Man Zhang
SCShu-Jian Chen
Shu-Jian Chen
WMWei Miao
Wei Miao
ZWZhi-Xin Wang
Zhi-Xin Wang
XZXiao-qun Zhu
Xiao-qun Zhu
Background: Neuroinflammation and hypertension are involved in Alzheimer’s disease (AD). However, their independent and additive impacts on astrocytes and AD-related pathologies have not been fully explored. Hence, this study investigated whether the associations between astrocyte reactivity, measured by cerebrospinal fluid (CSF), Chitinase 3-like protein 1 (CHI3L1/YKL-40), and AD-related pathologies were mediated by neuroinflammation and whether these associations were modified by hypertension. We also investigated the influence of hypertension on the relationship between baseline levels of CSF YKL-40 and longitudinal changes in cognitive function and brain structures.Methods: This study analyzed 288 participants from the AD Neuroimaging Initiative (ADNI) database. Multivariate linear regression, interaction, and subgroup analyses were conducted to explore the interrelationship between CSF YKL-40, AD biomarkers, neuroinflammation, cognitive function, and brain structures. Causal mediation analyses with 10,000 bootstrapped iterations were performed, using CSF YKL-40 as the independent variable and AD-related pathologies as the dependent variables, to explore mediation effects of neuroinflammation. Linear mixed-effects models were employed to study the associations between CSF YKL-40 and longitudinal changes in cognitive function and brain structures.Results: Higher baseline CSF YKL-40 levels were correlated with higher p-tau, t-tau, and neuroinflammatory biomarkers (ICAM1, VCAM1, sTNFR1, and sTNFR2), but with lower entorhinal cortex volume. Interaction showed that hypertension had a moderating influence on the associations between CSF YKL-40 and p-tau and t-tau. The significant associations of CSF YKL-40 with p-tau and t-tau were partially mediated by neuroinflammatory biomarkers (ICAM1, VCAM1, sTNFR1, and sTNFR2) in the whole sample (proportions: 13.0%∼78.8%). Similarly, the partial mediation effects of VCAM1, sTNFR1, and sTNFR2 on the aforementioned associations also existed in hypertensive subgroup (proportions: 17.9%∼50.3%). Additionally, higher baseline levels of CSF YKL-40 predicted faster decline in cognitive performance and brain atrophy (volumes of whole brain, hippocampus, entorhinal cortex, and middle temporal lobe) in the whole sample. Notably, subgroup analyses showed that the associations between higher CSF YKL-40 and faster brain atrophy were pronounced in hypertensive individuals.Conclusion: These findings suggest that neuroinflammation may mediate the relationship between astrocyte reactivity, measured by CSF YKL-40, and AD-related pathologies, with significant hypertensive dependency. Furthermore, elevated baseline CSF YKL-40 levels accelerated cognitive decline and brain atrophy, particularly in hypertensive individuals.


4 March 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
JCJing Cao
Jing Cao
PYPing Yan
Ping Yan
YZYajun Zhou
Yajun Zhou
XZXia Zhou
Xia Zhou
ZSZhongwu Sun
Zhongwu Sun
XZXiao-qun Zhu
Xiao-qun Zhu
We aimed to study the clinical utility of serum lipoprotein-associated phospholipase A2 (Lp-PLA2) in acute ischemic stroke (AIS) with cerebral artery stenosis (CAS). We included 200 AIS patients and 90 healthy controls in this study. AIS patients were classified into three subgroups depending on the severity of CAS. They were also classified based on the stability of the carotid plaques. Spearman correlation analysis was performed to determine the correlation relationship between the level of Lp-PLA2 and neurologic injury. Binary logistic regression analysis was performed to determine the independent risk factors for AIS. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic value of Lp-PLA2 for AIS and for the degree of CAS. We found that the serum level of Lp-PLA2 in AIS patients was significantly higher than that in the control group. Lp-PLA2 was further identified as an independent risk factor for AIS (p = 0.001, OR = 1.057). In addition, serum Lp-PLA2 level was the highest in AIS patients with severe CAS or occlusion. Lp-PLA2 level was higher in AIS patients with unstable plaques and in AIS patients with moderate to severe neurological injury. Lp-PLA2 level was positively correlated with National Institutes of Health Stroke Scale (NIHSS) score (r = 0.335, p = 0.001). We found that the optimal cut-off value for Lp-PLA2 level was 123.365 ng/ml, at which the sensitivity and specificity for the diagnosis of ACI were 74.5 and 86.7%, respectively, and the area under ROC curve (AUC) was 0.892. Similarly, the optimal value for Lp-PLA2 level was 136.46 ng/ml, at which the sensitivity and specificity for the diagnosis of the presence of moderate to severe artery stenosis or occlusion were 79.6 and 95.2%, respectively, and the AUC was 0.938. The ROC curve indicated that serum Lp-PLA2 level has an excellent diagnostic value for AIS and severe stenosis. Based on these results we conclude that Lp-PLA2 could be a potential biomarker to complement the current imaging methods in the prediction and diagnosis of AIS. An elevated Lp-PLA2 level is also correlated with carotid plaque instability, severe neurological injury and cerebrovascular stenosis. Future longitudinal studies are needed to determine whether there is a causative relationship between Lp-PLA2 and AIS.

26 June 2014 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
YWYu Wang
Yu Wang
MTMiao-Miao Tian
Miao-Miao Tian
XWXian-Hong Wang
Xian-Hong Wang
XZXiao-qun Zhu
Xiao-qun Zhu
YLYing Liu
Ying Liu
QPQing-Qing Pan
Qing-Qing Pan
A headache circumscribed in a line-shaped area but not confined to the territory of one particular nerve had ever been described in Epicrania Fugax (EF) of which the head pain is moving and ultrashort. In a 25-month period from Feb 2012 to Mar 2014, we encountered 12 patients with a paroxysmal motionless head pain restricted in a linear trajectory. The head pain trajectory was similar to that of EF, but its all other features obviously different from those of EF. We named this distinctive but undescribed type of headache linear headache (LH). A detailed clinical feature of the headache was obtained in all cases to differentiate with EF, trigeminal autonomic cephalalgias (TACs) and cranial neuralgia. Similarities and differences in clinical features were compared between LH and migraine. The twelve LH patients (mean age 43.9 ± 12.2) complained of a recurrent, moderate to severe, distending (n = 9), pressure-like (n = 3) or pulsating (n = 3) pain within a strictly unilateral line-shaped area. The painful line is distributed from occipital or occipitocervical region to the ipsilateral eye (n = 5), forehead (n = 6) or parietal region (n = 1). The pain line has a trajecory similar to that of EF but no characteristics of moving. The headache duration would be ranged from five minutes to three days, but usually from half day to one day in most cases (n = 8). Six patients had the accompaniment of nausea with or without vomiting, and two patients had the accompaniment of ipsilateral dizziness. The attacks could be either spontaneous (n = 10) or triggered by noise, depression and resting after physical activity (n = 1), or by stress and staying up late (n = 1). The frequency of attacks was variable. The patients had well response to flunarizine, sodium valproate and amitriptyline but not to carbamazepine or oxcarbazepine. LH is different from EF, trigeminal autonomic cephalalgias (TACs) and cranial neuralgia, but it had couple of features similar to that of migraine. The clinical picture of LH might be a subtype of migraine, or represent a novel syndrome.